uniQure N.V. (QURE)
After hours:
| Previous close | 19.94 |
| Open | 19.97 |
| Bid | 19.22 x 800 |
| Ask | 21.25 x 1200 |
| Day's range | 19.80 - 20.27 |
| 52-week range | 12.52 - 28.25 |
| Volume | |
| Avg. volume | 560,720 |
| Market cap | 942.388M |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 13, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 31 employees as a material inducement to commencing their employment. The equity awards were approved by the Company’s board of directors on February 23, 2023 (the “Grant Date”) in accordance with Nasdaq Listing Rule 5635(c
- GlobeNewswire
uniQure to Participate in Multiple Upcoming Industry Conferences in March
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Cowen Annual Healthcare Conference, March 6 – 8, 2023 Boston, MA Members of uniQure’s management team, including Matt Kapusta, chief executive officer, will participate in one-on-one i
- GlobeNewswire
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
~ Achieved U.S. and European Commission marketing approvals of first and only gene therapyfor adults with hemophilia B ~ ~ Advancing development of AMT-130 for patients with Huntington’s disease – clinical update from U.S. Phase I/II trial expected in second quarter 2023 ~ ~Hosted virtual investor event featuring AMT-260 in refractory temporal lobe epilepsy - expected to enter clinical development in second half of 2023 ~ ~Expanded pipeline with in-licensing of AMT-162 for SOD1 ALS - plans to in
